Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Viatris Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $116.97, while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Viatris Inc is trading nearer its 52-week high, Direxion NASDAQ 100 Equal Weighted Index Shares nearer its low. Which is the better fit depends on your goals.
| QQQE | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $122.72 | $17.59 |
52-Week Low | $96.06 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $116.70, down 0.09% on the day, with a mixed technical signal showing a bullish overall trend but bearish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a diversified alternative amid high market concentration, with SpaceX's upcoming Nasdaq-100 inclusion potentially driving passive inflows.
The outlook for QQQE is positive due to its defensive structure and uncorrelated performance, though technical indicators suggest near-term consolidation. Key risks include market volatility and reliance on growth stocks. Analyst sentiment is constructive, emphasizing its role in balanced Nasdaq exposure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
